Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 1234 results for pain

  1. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238

  2. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA448

  3. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA409

  4. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG639)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

    HealthTech guidance
    Published
    21 September 2022
    View recommendations

    Sections for HTG639

  5. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (HTG689)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

    HealthTech guidance
    Published
    9 August 2023
    View recommendations

    Sections for HTG689

  6. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  7. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  8. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  9. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

    Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA310

  10. Magseed for locating impalpable breast cancer lesions (MIB236)

    NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .

    Medtech innovation briefing
    Published
    17 November 2020

  11. Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

    Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA708

  12. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (HTG296)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    HealthTech guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for HTG296

  13. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this...

    Research recommendation
    Published
    30 September 2022

  14. Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (HTG318)

    Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.

    HealthTech guidance
    Published
    28 August 2013
    View recommendations

    Sections for HTG318

  15. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG303